WO2005108396A1 - 角結膜障害治療剤 - Google Patents
角結膜障害治療剤 Download PDFInfo
- Publication number
- WO2005108396A1 WO2005108396A1 PCT/JP2005/008584 JP2005008584W WO2005108396A1 WO 2005108396 A1 WO2005108396 A1 WO 2005108396A1 JP 2005008584 W JP2005008584 W JP 2005008584W WO 2005108396 A1 WO2005108396 A1 WO 2005108396A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethoxy
- methyl
- therapeutic agent
- corneal
- thiazolidinedione
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Keratoconjunctival disorder therapeutic agent Keratoconjunctival disorder therapeutic agent
- the present invention relates to a thiazolidinedione derivative, 5- [p- [2 (methyl-2-pyridylamino) ethoxy] benzyl] -2,4 thiazolidinedione, 5-[[4- [2- (5ethyl-2pyridin
- the present invention relates to a therapeutic agent for keratoconjunctival disorders such as dry eye, corneal ulcer, keratitis and conjunctivitis, which comprises ethoxy] phenyl] methyl] -2,4 thiazolidinedione or a salt thereof as an active ingredient.
- the cornea is a transparent avascular tissue having a diameter of about lcm and a thickness of about lmm
- the conjunctiva is a mucous membrane covering the surface of the eyeball behind the limbus and the back of the eyelid.
- conjunctiva are known to have important effects on visual function. Corneal conjunctival disorders caused by various diseases such as corneal ulcer, keratitis, conjunctivitis, dry eye, etc., if the repair is delayed for some reason or prolonged without repair, the cornea and conjunctiva are connected. As a tissue, it can adversely affect the normal construction of the epithelium, and can even damage the structure and function of the corneal stroma and endothelium.
- Non-Patent Document 1 Non-Patent Document 2
- Patent Document 1 describes an invention relating to a substituted thiazolidinedione derivative such as 5- [p- [2 (methyl-2-pyridylamino) ethoxy] benzyl] -2,4 thiazolidinedione (generic name: rosiglitazone). These compounds are said to be useful as therapeutics and preventives for hyperglycemia.
- Patent Document 2 discloses thiazolidine derivatives such as 5-[[4- [2- (5-ethyl-2-pyridyl) ethoxy] phenyl] methyl] 2,4 thiazolidinedione (generic name: pioglitazone) And a compound having a blood glucose and blood lipid lowering effect and useful as a therapeutic agent for diabetes.
- Patent Document 3 states that insulin sensitizers such as rosiglitazone and pioglitazone are It is disclosed that it is effective as a therapeutic agent for sexual diseases.
- Patent Document 1 Japanese Patent No. 2614497
- Patent Document 2 JP-A-61-267580
- Patent Document 3 International Publication No.02Z13812 pamphlet
- Non-patent document 1 Rinkai, 46, 738-743 (1992)
- Non-patent Document 2 Ophthalmic surgery, 5, 719-727 (1992)
- the search for new pharmaceutical uses of [phenyl] methyl] -2,4-thiazolidinedione is an interesting and challenging task.
- the present inventors have conducted intensive studies in search of a new pharmaceutical use of the above compound.
- a corneal disorder healing efficacy test using a corneal disorder model the above compound or a salt thereof showed no corneal disorder.
- the present invention was found to exhibit an excellent improvement effect on the present invention, leading to the present invention.
- the present invention relates to 5- [p- [2- (methyl-2-pyridylamino) ethoxy] benzyl tyl-2-pyridyl) ethoxy] phenyl] methyl] -2,4 thiazolidinedione (hereinafter referred to as "pioglitazone"). Or a salt thereof as an active ingredient for treating corneal conjunctival disorders such as dry eye, corneal ulcer, keratitis and conjunctivitis.
- the rosiglitazone and pioglitazone of the present invention are thiazolidinedione derivatives represented by the following chemical structural formulas, respectively.
- the rosiglitazone or pioglitazone salt of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt, salts with inorganic acids such as hydrochloric acid, nitric acid and sulfuric acid, acetic acid, fumaric acid and maleic acid. And salts with organic acids such as succinic acid and tartaric acid. More preferred salts are the hydrochloride and maleate.
- the quaternary ammonium salt of rosiglitazone or pioglitazone of the present invention is also included in the salts of the present invention.
- the rosiglitazone or pioglitazone of the present invention may be in the form of hydrates and solvates! / ⁇ .
- geometric isomers, optical isomers, tautomers, polymorphs, and the like of rosiglitazone and pioglitazone are also included in the scope of the present invention.
- corneal conjunctival disorder refers to a condition in which the cornea or conjunctiva is damaged due to various factors, and includes, for example, dry eye, corneal ulcer, keratitis, conjunctivitis and the like.
- the therapeutic agent for keratoconjunctival disorders of the present invention can be administered orally or parenterally.
- Dosage forms include eye drops, eye ointments, injections, tablets, capsules, granules, powders, etc., with eye drops being particularly preferred. These can be formulated using commonly used techniques.
- eye drops include isotonic agents such as sodium chloride, concentrated glycerin, buffering agents such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monolate, polyoxyl 40 stearate, polyoxyethylene.
- It can be prepared by using a surfactant such as hydrogenated castor oil, a stabilizer such as sodium citrate and sodium edetate, a preservative such as benzalcodium salt, paraben and the like as needed.
- a surfactant such as hydrogenated castor oil
- a stabilizer such as sodium citrate and sodium edetate
- a preservative such as benzalcodium salt, paraben and the like
- the pH of the eye drops should be within the range allowed for ophthalmic preparations, but preferably in the range of 4 to 8!
- An eye ointment can be prepared using a commonly used base such as white petrolatum or liquid paraffin.
- Oral preparations such as tablets, capsules, granules and powders include lactose, crystalline cellulose, bulking agents such as starch, vegetable oil, lubricating agents such as magnesium stearate and talc, hydroxypropylcellulose and polybutyl.
- Binders such as pyrrolidone, disintegrants such as carboxymethylcellulose calcium and low-substituted hydroxypropylmethylcellulose, coating agents such as hydroxypropylmethylcellulose, macrogol, silicone resin, and coating agents such as gelatin film as required And can be prepared.
- the dose can be appropriately selected depending on the symptoms, age, dosage form, etc ..
- wZv preferably 0.001 to 1% (wZv) may be instilled once or several times a day.
- 0.1 to 5000 mg, preferably 1 to: LOOO mg per oral dose may be administered once or in several divided doses.
- both rosiglitazone and pioglitazone hydrochloride of the present invention exhibited excellent ameliorating effects in a corneal disorder model. It is useful as a therapeutic agent for keratoconjunctival disorders such as keratitis and conjunctivitis.
- a corneal disorder model was prepared according to the method of Fujihara et al. (Invest. Ophthalmol. Vis. Sci 42 (1): 96-100 (2001)). After the corneal disorder model was created, the method was modified according to the method of Takada et al. (Ophthalmological Clinicians 48 (2): 183-188 (1994)) (New Ophthalmology 21 (1): 87-90 (2004) ), The cure rate of the corneal disorder was determined.
- Nembutal was administered to male SD rats to perform general anesthesia. The extraorbital lacrimal gland was then removed and corneal damage was induced over a two-month period. Next, the present compound (mouth ciglitazone, pioglitazone hydrochloride) was administered as follows.
- a rosiglitazone (0.02%) saline solution was instilled into both eyes 6 times a day for 14 days (8 animals per group).
- a physiological saline solution of pioglitazone hydrochloride (0.01%) was instilled into both eyes 6 times a day for 14 days (8 animals per group).
- the damaged part of the cornea was stained with fluorescein.
- the degree of staining with fluorescein was determined for each of the upper, middle and lower parts of the cornea according to the following criteria, and the corneal disorder improvement rate was calculated from the average of the sum of the scores of each part.
- Staining is moderate, and a part of the dot-like stained portion is adjacent.
- the mean score of the control group (physiological saline) as the standard (improvement rate: 0%)
- the improvement in the rosiglitazone (0.02%) ophthalmic group and the pioglitazone (0.01%) ophthalmic group was calculated according to the following formula. The rate was calculated. These are shown in Table 1.
- the average of the scores is the average of eight cases.
- Improvement rate (%) ⁇ (control-rule)-(hon-i-dori)) / disability X 100
- rosiglitazone and pioglitazone significantly improve corneal damage.
- the concentrations are 0.001% (w / v), 0.03% (w Zv), 0.1% (WZV), 0.3% (w / v). v), 1.0% (wZv) and 3.0% (wZv) eye drops can be prepared.
- an ointment having a concentration of 1% (w / w) or 3% (wZw) can be prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002566098A CA2566098A1 (en) | 2004-05-11 | 2005-05-11 | Therapeutic agent for keratoconjunctival disorder |
EP05739114A EP1757603A4 (en) | 2004-05-11 | 2005-05-11 | THERAPEUTIC AGENT FOR KERAATOCONJUNCTIVITIS AFFECTION |
US11/595,258 US20070054943A1 (en) | 2004-05-11 | 2006-11-09 | Therapeutic agent for keratoconjunctival disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004141012 | 2004-05-11 | ||
JP2004-141012 | 2004-05-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/595,258 Continuation-In-Part US20070054943A1 (en) | 2004-05-11 | 2006-11-09 | Therapeutic agent for keratoconjunctival disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005108396A1 true WO2005108396A1 (ja) | 2005-11-17 |
Family
ID=35320176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008584 WO2005108396A1 (ja) | 2004-05-11 | 2005-05-11 | 角結膜障害治療剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070054943A1 (ja) |
EP (1) | EP1757603A4 (ja) |
KR (1) | KR20070011497A (ja) |
CN (1) | CN1956981A (ja) |
CA (1) | CA2566098A1 (ja) |
WO (1) | WO2005108396A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136129A1 (en) * | 2006-05-23 | 2007-11-29 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2716418A1 (en) * | 2008-02-25 | 2009-09-03 | Santen Pharmaceutical Co., Ltd. | Agent for enhancing corneal epithelial barrier function |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11279062A (ja) * | 1998-01-30 | 1999-10-12 | Fujisawa Pharmaceut Co Ltd | 眼科用剤 |
WO2002013812A1 (en) * | 2000-08-17 | 2002-02-21 | Pershadsingh Harrihar A | Methods for treating inflammatory diseases |
JP2004509961A (ja) * | 2000-09-26 | 2004-04-02 | ドクター・レディーズ・リサーチ・ファウンデーション | 5−[4−[2−[n−メチル−n−(2−ピリジル)アミノ]エトキシ]ベンジル]チアゾリジン−2,4−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
JP3059092B2 (ja) * | 1995-11-15 | 2000-07-04 | 田辺製薬株式会社 | ドライアイおよびドライアイを原因とする疾患の予防・治療剤 |
WO1999038497A2 (en) * | 1998-01-30 | 1999-08-05 | R-Tech Ueno, Ltd. | Ophthalmic composition |
WO2000000194A1 (en) * | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
US20040034067A1 (en) * | 1999-04-15 | 2004-02-19 | Macphee Colin Houston | Novel method of treatment |
US7241895B2 (en) * | 2000-09-26 | 2007-07-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
FR2826278B1 (fr) * | 2001-06-20 | 2005-03-25 | Lipha | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
-
2005
- 2005-05-11 KR KR1020067023841A patent/KR20070011497A/ko not_active Application Discontinuation
- 2005-05-11 EP EP05739114A patent/EP1757603A4/en not_active Withdrawn
- 2005-05-11 CA CA002566098A patent/CA2566098A1/en not_active Abandoned
- 2005-05-11 CN CNA2005800150968A patent/CN1956981A/zh active Pending
- 2005-05-11 WO PCT/JP2005/008584 patent/WO2005108396A1/ja active Application Filing
-
2006
- 2006-11-09 US US11/595,258 patent/US20070054943A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11279062A (ja) * | 1998-01-30 | 1999-10-12 | Fujisawa Pharmaceut Co Ltd | 眼科用剤 |
WO2002013812A1 (en) * | 2000-08-17 | 2002-02-21 | Pershadsingh Harrihar A | Methods for treating inflammatory diseases |
JP2004509961A (ja) * | 2000-09-26 | 2004-04-02 | ドクター・レディーズ・リサーチ・ファウンデーション | 5−[4−[2−[n−メチル−n−(2−ピリジル)アミノ]エトキシ]ベンジル]チアゾリジン−2,4−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法 |
Non-Patent Citations (7)
Title |
---|
CHIKAMA T. ET AL: "Senensei kakumaku Johi Kesson.", vol. 43, no. 12, 2001, pages 1625 - 1631, XP002989348 * |
HARA M. ET AL: "Idensei II gata Tonyobyo GK Rat no okeru Kakumaku Johi Saibo no Zoshoku oyobi Bunka no Hen'i.", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY., vol. 109, 2005, pages 272, XP002994402 * |
HARINO S. ET AL: "Tonyobyosei Kakumakusho no 1 Rei to sono Kakumaku Niihi Saibo Shoken.", FOLIA OPHTHALMOLOGICA JAPONICA., vol. 40, 1989, pages 2124 - 2130, XP002994298 * |
HOSOTANI H. ET AL: "Tonyobyosei Kakumakusho.", THE JOURNAL OF THE EYE., vol. 13, no. 6, 1996, pages 845 - 851, XP002989346 * |
KISANUKI M ET AL: "Jutoku na Kosaien o Tomonatta Tonyobyo Kakumakusho no 2 Rei.", FOLIA OPHTHALMPLOGICA JAPONICA., vol. 46, 1995, pages 268 - 271, XP002994300 * |
TAKANO Y ET AL: "Tonyobyo Kakumaku Johisho no 3 Rei.", JAPANESE REVIEW OF CLINICAL OPHTHALMOLOGY., vol. 92, no. 8, 1989, pages 1102 - 1105, XP002994299 * |
WATANABE H ET AL: "Corneal Disorders in KKAy Mouse: A Type 2 Diabetes Model.", JPN J OPHTHALMOL., vol. 46, 2002, pages 130 - 139, XP002994401 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136129A1 (en) * | 2006-05-23 | 2007-11-29 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
US8865217B2 (en) | 2006-05-23 | 2014-10-21 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
Also Published As
Publication number | Publication date |
---|---|
EP1757603A4 (en) | 2008-06-25 |
US20070054943A1 (en) | 2007-03-08 |
CA2566098A1 (en) | 2005-11-17 |
CN1956981A (zh) | 2007-05-02 |
KR20070011497A (ko) | 2007-01-24 |
EP1757603A1 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4217832B2 (ja) | 角結膜障害の治療剤 | |
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
JP2020531511A (ja) | 眼球用医薬組成物 | |
WO2005108396A1 (ja) | 角結膜障害治療剤 | |
US7348329B2 (en) | Therapeutic agent for keratoconjunctival disorder | |
JP4922588B2 (ja) | 角結膜障害治療剤 | |
JP2005350451A (ja) | 角結膜障害治療剤 | |
WO2007066678A1 (ja) | 角結膜障害治療剤 | |
EP1790338A1 (en) | Therapeutic agent for keratoconjunctiva disorder | |
JP2006104199A (ja) | 角結膜障害治療剤 | |
JP2007291091A (ja) | 角結膜障害治療剤 | |
JP2005162735A (ja) | 角結膜障害治療剤 | |
JP5087233B2 (ja) | 角結膜障害の予防または治療剤 | |
EP1872783B1 (en) | Therapeutic agent for corneal/conjunctival disorder | |
WO2007114315A1 (ja) | 角結膜障害治療剤 | |
JP4697027B2 (ja) | 角結膜障害治療剤 | |
JP2007182435A (ja) | 角結膜障害治療剤 | |
CN101229166A (zh) | 角膜结膜病变治疗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2566098 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11595258 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580015096.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067023841 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005739114 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067023841 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005739114 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11595258 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |